Animal Models in Toxicology

A special issue of Biology (ISSN 2079-7737). This special issue belongs to the section "Toxicology".

Deadline for manuscript submissions: 31 January 2025 | Viewed by 2991

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biological & Biomedical Sciences, North Carolina Central University, Durham, NC 27707, USA
Interests: toxicology; pulmonary; calcium signaling; lung physiology; kinases; ion channel biology; high throughput screening; drug discovery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

For an animal model of toxicology to be relevant to human health, the route of administration/exposure, the exposure dose(s) and the pattern/frequency of doses should all be justified and defined in terms of overall applicability to human physiology and potential physiological disruption and then ideally similar across studies to allow for comparisons between and among studies. This set of statements should be arguably true independent of chemical, drug, etc. being scientifically assessed/studied. However, complexities will, of course, exist and include questions surrounding route of exposure, e.g., dermal, ingestion or inhalation. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: studies aimed at the development and/or use of (novel) animal models to address human health concerns related to chemically defined substances, such as drugs, with regard to well-perceived or as of yet not perceived toxicological effects; using animal models to study or derive new biomarkers of harm; or studies aimed at exploring or defining the numerous routes of exposure of a single chemical. Appropriate and thorough reviews of existing animal models of toxicology would also be especially welcomed.

Dr. Rob U. Onyenwoke
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • animal model
  • biomarker of harm
  • pharmacokinetics
  • route of exposure
  • toxicology
  • toxin

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 2223 KiB  
Article
Dapagliflozin: A Promising Strategy to Combat Cisplatin-Induced Hepatotoxicity in Wistar Rats
by Shakta Mani Satyam, Laxminarayana Kurady Bairy, Abdul Rehman, Mohamed Farook, Sofiya Khan, Anuradha Asokan Nair, Nirmal Nachiketh Binu, Mohamed Yehya and Mohammed Moin Khan
Biology 2024, 13(9), 672; https://doi.org/10.3390/biology13090672 - 29 Aug 2024
Viewed by 823
Abstract
Recognizing the challenges posed by chemotherapy, specifically the hepatotoxic effects of drugs like cisplatin, this study aimed to examine the hepatoprotective potential of dapagliflozin to mitigate cisplatin-induced hepatotoxicity in a rat model. This study focused on repurposing drugs such as dapagliflozin and natural [...] Read more.
Recognizing the challenges posed by chemotherapy, specifically the hepatotoxic effects of drugs like cisplatin, this study aimed to examine the hepatoprotective potential of dapagliflozin to mitigate cisplatin-induced hepatotoxicity in a rat model. This study focused on repurposing drugs such as dapagliflozin and natural agents like silymarin as potential interventions to address cisplatin-induced hepatotoxicity. Thirty adult female Wistar rats were distributed into five groups and treated with cisplatin alone, silymarin, dapagliflozin, or a combination of dapagliflozin and silymarin accordingly for 45 days. Body weight, fasting blood glucose levels, liver function tests, and histopathological analysis were conducted to evaluate the hepatoprotective effects. Cisplatin-induced hepatotoxicity significantly (p < 0.05) increased the serum levels of ALT, AST, TB, and reduced the TP and albumin levels. Dapagliflozin administration led to significant reductions in ALT, AST, TB, and increased albumin levels. Silymarin demonstrated comparable effects. Combining dapagliflozin and silymarin showed synergistic effects, further reducing the liver enzymes and improving albumin levels. Histopathological examination supported these findings, revealing the restoration of liver structure with dapagliflozin and silymarin treatment. Dapagliflozin and silymarin exhibited substantial hepatoprotective benefits against cisplatin-induced hepatotoxicity in rats. The combination therapy demonstrated synergistic effects, highlighting a potential therapeutic approach for mitigating chemotherapy-induced liver damage. Further research into molecular mechanisms and clinical translation is warranted, offering hope for improved clinical outcomes in cancer patients undergoing cisplatin-based chemotherapy. Full article
(This article belongs to the Special Issue Animal Models in Toxicology)
Show Figures

Figure 1

16 pages, 3773 KiB  
Article
Unlocking Synergistic Hepatoprotection: Dapagliflozin and Silymarin Combination Therapy Modulates Nuclear Erythroid 2-Related Factor 2/Heme Oxygenase-1 Pathway in Carbon Tetrachloride-Induced Hepatotoxicity in Wistar Rats
by Shakta Mani Satyam, Laxminarayana Kurady Bairy, Abdul Rehman, Mohamed Attia, Layth Ahmed, Karam Emad, Yusuf Jaafer and Abdelrehman Bahaaeldin
Biology 2024, 13(7), 473; https://doi.org/10.3390/biology13070473 - 26 Jun 2024
Cited by 2 | Viewed by 1627
Abstract
This study was aimed to investigate the hepatoprotective potential of dapagliflozin and silymarin alone and in combination to combat carbon tetrachloride (CCl4)-induced hepatotoxicity and the anticipated mechanisms. Thirty female Wistar rats were randomly allocated into five different groups. All the experimental [...] Read more.
This study was aimed to investigate the hepatoprotective potential of dapagliflozin and silymarin alone and in combination to combat carbon tetrachloride (CCl4)-induced hepatotoxicity and the anticipated mechanisms. Thirty female Wistar rats were randomly allocated into five different groups. All the experimental animals except the normal control (Group I) were administered CCl4. Additionally, Groups II, III, IV, and V were treated with gum acacia, silymarin, dapagliflozin, and a combination of dapagliflozin and silymarin, respectively, for 14 days. Dapagliflozin, silymarin alone, and in combination, significantly reduced (p < 0.05) serum levels of ALT, AST, AST:ALT ratio, and total bilirubin compared to CCl4-intoxicated control rats. There was a notable reduction (p < 0.05) observed in the levels of IL-1beta, IL-6, TNF-alpha, nitrites, and 4-hydroxynonenal, accompanied by an elevation in catalase, superoxide dismutase, glutathione peroxidase, nuclear erythroid 2-related factor 2 (Nrf2), and heme oxygenase-1 (HO-1) in liver homogenates of the groups treated with dapagliflozin, silymarin alone, and in combination, as compared to the CCl4-intoxicated control group. Dapagliflozin in combination with silymarin showed a synergistic hepatoprotective effect. Our study reveals the profound hepatoprotective potential of dapagliflozin alone and in combination with silymarin in CCl4-intoxicated Wistar rats by modulating the Nrf2 and HO-1 signaling pathways. Full article
(This article belongs to the Special Issue Animal Models in Toxicology)
Show Figures

Figure 1

Back to TopTop